



J. B. Chemicals & Pharmaceuticals Limited

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.
 Corporate Office : Cnergy IT Park, Unit A2, 3rd Floor, Unit A, 8th Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai – 400 025.
 Phone: 022-2439 5200 / 2439 5500 Fax : 022 – 2431 5331/ 24131 5334
 CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2017

(Rs. in lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Year ended		Consolidated Year ended	
		31-03-2017	31-12-2016	31-03-2016	31-03-2017	31-03-2016	31-03-2017	31-03-2016
		Audited (refer note 7)	Unaudited	Audited	Audited	Audited	Audited	Audited
1	Revenue from Operations	30,626.19	27,648.17	30,275.91	1,19,869.42	1,16,493.57	1,36,831.70	1,23,158.31
2	Other Income	1,276.27	769.05	2,005.14	4,589.03	5,567.60	5,015.70	5,665.36
3	Total Income (1+2)	31,902.46	28,417.22	32,281.05	1,24,458.45	1,22,061.17	1,41,847.40	1,28,823.67
4	Expenses							
	a. Cost of materials consumed	9,131.39	8,230.94	8,967.58	36,709.36	37,307.84	36,709.36	37,307.84
	b. Purchases of stock-in-trade	2,857.52	2,320.23	2,868.96	9,624.47	8,254.88	15,244.24	11,062.85
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(663.24)	(276.94)	(698.68)	(1,805.26)	(684.05)	843.13	(1,351.43)
	d. Employees benefits expense	4,989.62	4,702.63	4,671.16	18,786.11	16,595.97	20,654.37	17,530.68
	e. Finance Costs	(24.05)	243.00	209.80	500.13	1,029.48	537.16	1,064.59
	f. Depreciation and amortization expense	1,240.46	1,135.96	1,037.31	4,626.42	4,040.87	4,722.44	4,122.23
	g. Other Expenses	9,623.41	8,097.60	8,896.53	34,338.86	32,446.84	40,142.29	38,005.28
	Total Expenses (4)	27,155.11	24,453.42	25,952.66	1,02,780.09	98,991.83	1,18,852.99	1,07,742.04
5	Profit before Tax and share of joint venture (3-4)	4,747.35	3,963.80	6,328.39	21,678.36	23,069.34	22,994.41	21,081.63
6	Share of Profit of joint venture	-	-	-	-	-	-	141.47
7	Profit before Tax (5+6)	4,747.35	3,963.80	6,328.39	21,678.36	23,069.34	22,994.41	21,223.10
8	Tax expenses	532.44	387.70	1,274.79	4,381.90	5,149.05	4,554.59	4,958.04
9	Net Profit/(Loss) after Tax before non controlling interest(7-8)	4,214.91	3,576.10	5,053.60	17,296.46	17,920.29	18,439.82	16,265.05
10	Non controlling interest	-	-	-	-	-	33.55	10.40
11	Net Profit/(Loss) after Tax and non controlling interest (9-10)	4,214.91	3,576.10	5,053.60	17,296.46	17,920.29	18,406.27	16,254.65
12	Other Comprehensive Income (net of Tax)	(246.21)	(8.08)	(7.75)	(270.43)	(30.98)	(270.43)	(30.98)
13	Total Comprehensive Income after Tax (11+12)	3,968.70	3,568.02	5,045.85	17,026.03	17,889.31	18,135.84	16,223.67
14	(I) Earning per share(EPS) (of Rs. 2/- each not annualised)							
	(1) Basic	4.68	4.21	5.95	20.07	21.09	21.42	19.14
	(2) Diluted	4.68	4.21	5.95	20.07	21.09	21.42	19.14

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on May 23, 2017.
- The financial results for the quarter and year ended on March 31, 2017 have been prepared in accordance with new accounting standards prescribed under Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) applicable to the Company w.e.f. April 1, 2016. (Transition date April 1, 2015)
- The reconciliation between net profit for the quarter and year ended March 31, 2016 reported earlier as per previous Indian GAAP and the one recast as above as per Ind AS as well as the reconciliation of equity for year ended on March 31, 2016 reported earlier as per previous Indian GAAP and the one recast as above as per Ind AS is as under:

(Rs. in lakhs)

Particulars	Profit Reconciliation		Reconciliation of Equity
	Quarter ended March 31, 2016	Year ended on March 31, 2016	As At March 31, 2016
Other Equity as per previous Indian GAAP	-	-	1,12,478.57
Net profit reported for March 2016 as per previous Indian GAAP	4,322.91	17,638.85	-
Actuarial loss on defined benefit plans reclassified to other comprehensive Income	11.85	47.38	-
Net gain/(loss) arising on fair valuation of Investments	1,083.30	268.27	9,861.77
Net gain/(loss) arising on fair Fair valuation of Forward Contracts	(97.00)	43.98	(1.11)
Others	(13.42)	0.11	(0.21)
Deferred Tax Impact on above Adjustments	(254.04)	(78.30)	(2,275.32)
Reversal of Proposed dividend	-	-	510.44
Net Profit/(Loss) after Tax as per Ind AS	5,053.60	17,920.29	-
Other Equity as per Ind AS	-	-	1,20,574.14

- The Company has one reportable segment viz. Pharmaceuticals.
- The Board of Directors has recommended a dividend of Re. 1 per equity share of face value of Rs. 2 (50%).
- The Board of Directors has approved the buy-back of up to 12,50,000 fully paid up equity shares of face value of Rs. 2/- each by the Company (representing 1.47% of the total paid up Equity Share capital of the Company) at a price of Rs. 400 per Equity Share for a total consideration not exceeding Rs. 50.00 crores (excluding transaction costs).
- Figures pertaining to last quarter are balancing figures between audited figures in respect of full financial year and published and reviewed year-to-date figures up to the end of third quarter of the relevant financial year.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

(Rs. in lakhs)

Particulars	Standalone		Consolidated	
	As at March 31,2017	As at March 31,2016	As at March 31,2017	As at March 31,2016
ASSETS				
(I) Non-current assets				
(a) Property, Plant and Equipment	59,366.61	36,796.94	59,727.03	37,155.25
(b) Capital work-in-progress	376.25	13,418.52	376.25	13,418.52
(c) Goodwill	-	-	5,314.00	5,314.00
(d) Other Intangible assets	1,502.41	138.45	2,903.39	1,552.73
(e) Intangible assets under development	-	70.48	-	70.48
(f) Financial Assets				
(i) Investments	31,880.88	36,438.23	18,584.20	23,141.55
(ii) Trade receivables	-	-	-	-
(ii) Loans	30.43	15.34	30.43	15.34
(iv) Others	648.77	501.16	648.77	697.16
(g) Other non-current assets	330.76	1,779.63	330.76	1,793.28
TOTAL non current assets	94,136.11	89,158.75	87,914.84	83,158.31
(II) Current assets				
(a) Inventories	15,995.57	13,329.31	20,016.86	18,798.33
(b) Financial Assets				
(i) Investments	22,496.16	24,728.31	22,496.16	24,728.31
(ii) Trade receivables	26,509.52	26,566.79	26,596.62	27,264.17
(iii) Cash and cash equivalents	719.71	1,070.58	1,338.64	1,290.22
(iv) Loans	44.32	56.51	92.61	74.64
(vi) Others	95.57	411.45	114.05	413.39
(c) Other current assets	8,440.31	8,811.79	8,834.07	9,038.65
TOTAL current assets	74,301.16	74,974.73	79,489.02	81,607.71
Total Assets	1,68,437.27	1,64,133.48	1,67,403.86	1,64,766.02
EQUITY AND LIABILITIES				
Equity				
(a) Equity Share capital	1,696.40	1,696.40	1,696.40	1,696.40
(b) Other Equity	1,37,089.73	1,20,574.14	1,34,670.51	1,16,687.43
(c) non controlling interest			218.05	166.50
Total Equity	1,38,786.13	1,22,270.54	1,36,584.96	1,18,550.33
LIABILITIES				
(I) Non-current liabilities				
(a) Provisions	888.01	1,020.11	1,256.20	1,043.29
(b) Deferred tax liabilities (Net)	2,895.35	3,206.57	1,046.38	1,677.63
(c) Other non-current liabilities	395.48	380.60	395.48	380.60
TOTAL non current Liabilities	4,178.84	4,607.28	2,698.06	3,101.52
(II) Current liabilities				
(a) Financial Liabilities				
(i) Borrowings	4,886.03	17,440.19	4,886.03	19,302.37
(ii) Trade payables	7,903.47	6,860.93	9,897.71	9,085.09
(iii) Other financial liabilities	10,977.95	11,504.18	11,376.26	13,811.57
(b) Other current liabilities	830.07	398.79	838.44	61.71
(c) Provisions	787.39	622.69	1,035.01	811.79
(d) Current Tax Liabilities (Net)	87.39	428.89	87.39	41.64
TOTAL Current Liabilities	25,472.30	37,255.67	28,120.84	43,114.17
Total Equity and Liabilities	1,68,437.27	1,64,133.48	1,67,403.86	1,64,766.02

For J.B. Chemicals & Pharmaceuticals Ltd.



J.B.Mody

Chairman & Managing Director

Place : Mumbai

Date : 23/05/2017